


=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 12:52:28 ON 12 APR 2007)

FILE 'REGISTRY' ENTERED AT 12:52:40 ON 12 APR 2007

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 0 S L2
L4 7 S L2 FUL


FILE 'CAPLUS' ENTERED AT 12:53:14 ON 12 APR 2007

L5 2 S L4


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.01	183.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 12:54:04 ON 12 APR 2007

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1989:205054 CAPLUS Full-text
 DN 110:205054
 TI 5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents
 AU Meyer, Walter E.; Tomcufcik, Andrew S.; Chan, Peter S.; Haug, Margie
 CS Lederle Lab., Am. Cyanamid Co., Pearl River, NY, 10965, USA
 SO Journal of Medicinal Chemistry (1989), 32(3), 593-7
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 110:205054
 GI





AB A series of 5-(1-piperazinyl)-1H-1,2,4-triazol-3-amines was synthesized and screened for antihypertensive and diuretic activity in spontaneously hypertensive rats (SHR). One compound, 5-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-1H-1,2,4-triazol-3-amine (I), was selected to define the mechanism of its antihypertensive activity. Studies in spontaneously hypertensive rats suggest ganglionic blocking activity. Short-lived antihypertensive activity was observed in conscious renal hypertensive dogs. Structure-activity relationships are discussed. None of the prepared and tested compds. had diuretic activity.
 IT 118630-52-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction with hydrazine hydrate)
 RN 118630-52-7 CAPLUS
 CN 1-Piperazinecarboximidothioic acid, N-cyano-4-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:20683 CAPLUS Full-text
 DN 140:94064
 TI Preparation of cyanoiminopiperazines for treating pain
 IN Kyle, Donald J.; Sun, Qun; Tafesse, Laykea; Zhang, Chongwu; Zhou, Xiaoming
 PA Euro-Celtique, S. A., Luxembourg
 SO PCT Int. Appl., 287 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002983	A2	20040108	WO 2003-US20509	20030627
	WO 2004002983	A3	20040318		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2491079	A1	20040108	CA 2003-2491079	20030627
	AU 2003247829	A1	20040119	AU 2003-247829	20030627
	US 2004106625	A1	20040603	US 2003-607563	20030627
	BR 2003012322	A	20050412	BR 2003-12322	20030627
	EP 1556354	A2	20050727	EP 2003-762220	20030627
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1678585	A	20051005	CN 2003-820137	20030627
	JP 2005535731	T	20051124	JP 2004-549842	20030627
	NZ 537292	A	20060831	NZ 2003-537292	20030627
	NO 2005000371	A	20050317	NO 2005-371	20050124
PRAI	US 2002-391962P	P	20020628		
	US 2002-411030P	P	20020917		
	US 2002-413148P	P	20020925		
	US 2002-416582P	P	20021008		
	WO 2003-US20509	W	20030627		
OS	MARPAT 140:94064				
GI					



AB The title compds. [I; A = NR₄, O, S; R₁ = halo, Me, NO₂, CN, etc.; R₂ = halo, CN, alkyl, aryl, etc.; R₃ is not defined; R₄ = alkyl, alkoxy; R₆ = Ph, naphthyl, cycloalkyl, etc.; n = 0-3; m = 0-2], useful for treating or preventing pain, urinary incontinence, ulcer, inflammatory bowel disease,


irritable bowel syndrome, addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, seizure, a pruritic condition, psychosis, cognitive disorder, memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, muscle spasm, migraine, vomiting, dyskinesia or depression in an animal, were prepared. Thus, reacting 2-(1-cyclohexenyl)ethylamine with diphenylcyanocarbodimide in 2-methoxyethyl ether followed by addition of (R)-1-(3-chloropyridin-2-yl)-3-methylpiperazine afforded II which showed IC₅₀ of 59.4±13.1 nM in capsaicin-based VR1 assay. These compounds I were tested for binding to mGluR5, mGluR1, and to VR1. The pharmaceutical composition comprising the compound I is claimed.

IT 642457-82-7P 642457-83-8P 642457-84-9P
642457-85-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyanoiminopiperazines for treating pain)


RN 642457-82-7 CAPLUS

CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 642457-83-8 CAPLUS

CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-84-9 CAPLUS

CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 642457-85-0 CAPLUS

CN 1-Piperazinecarboximidamide, 4-(3-chloro-2-pyridinyl)-N-cyano-N'-[2-(1-cyclohexen-1-yl)ethyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

